Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054)

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 1, 2011, Pages 99-113

  Dawson, Nancy ^a   Payne, Heather ^b   Battersby, Clare ^c   Taboada, Maria ^c   James, Nick ^d  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

EORTC QLQ C30; FACT P; Health related quality of life (HRQoL); Hormone resistant prostate cancer (HRPC); Zibotentan

Indexed keywords

PLACEBO; ZIBOTENTAN; ANTINEOPLASTIC AGENT; ENDOTHELIN A RECEPTOR ANTAGONIST; PYRROLIDINE DERIVATIVE;

ADULT; AGED; ALLERGIC RHINITIS; ARTHRALGIA; ARTICLE; BACKACHE; BONE METASTASIS; CANCER GROWTH; CONSTIPATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; FATIGUE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY PROSTATE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NOSE CONGESTION; PATIENT ATTITUDE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; MIDDLE AGED; PROSTATIC NEOPLASMS; PSYCHOLOGY; QUESTIONNAIRE; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, NEOPLASM; ENDOTHELIN A RECEPTOR ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; PYRROLIDINES; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 78751620797     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0864-1     Document Type: Article

References (14)

1. NK Aaronson S Ahmedzai B Bergman M Bullinger A Cull NJ Duez A Filiberti H Flechtner SB Fleishman JC de Haes 1993 The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 365 376 1:STN:280:DyaK3s7msVarsQ%3D%3D 10.1093/jnci/85.5.365 8433390
2. DR Berthold GR Pond M Roessner R de Wit M Eisenberger IF Tannock On behalf of the TAX-327 investigators 2008 Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study Clin Cancer Res 14 2763 2767 1:CAS:528:DC%2BD1cXlsV2qurY%3D 10.1158/1078-0432.CCR-07-0944 18451243
3. G Borghede M Sullivan 1996 Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30 Qual Life Res 5 212 222 1:STN:280:DyaK2s7gsVOjtQ%3D%3D 10.1007/BF00434743 8998490 (Pubitemid 26180669)
4. DF Cella DS Tulsky G Gray B Sarafian E Linn A Bonomi M Silberman SB Yellen P Winicour J Brannon 1993 The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J Clin Oncol 11 570 579 1:STN:280:DyaK3s7oslKqsQ%3D%3D 8445433
5. D Cella MB Nichol D Eton J Nelson P Mulani 2008 Estimating clinically meaningful changes for the functional assessment of cancer therapy-prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer Value Health 12 124 129 10.1111/j.1524-4733.2008.00409.x 18647260
6. P Esper F Mo G Chodak M Sinner D Cella KJ Pienta 1997 Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument Urology 50 920 928 1:STN:280:DyaK1c%2FovVWgsg%3D%3D 10.1016/S0090-4295(97)00459-7 9426724 (Pubitemid 28021111)
7. Fayers P, Aaronson N, Bjordal K, Sullivan M (1995) EORTC QLQ-C30 scoring manual. EORTC Data Centre, Brussels
8. K Fizazi K Miller 2009 Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer BJU Int 104 1423 1425 1:CAS:528: DC%2BD1MXhsFaiur7O 10.1111/j.1464-410X.2009.08740.x 19624592
9. JW Growcott 2009 Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054 Anticancer Drugs 20 83 88 1:CAS:528:DC%2BD1MXhvVSitLs%3D 10.1097/CAD.0b013e328320791c 19065106
10. ND James A Caty M Borre BA Zonnenberg P Beuzeboc T Morris D Phung NA Dawson 2009 Safety and efficacy of the specific endothelin A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomized, Phase II trial Eur Urol 55 1112 1123 1:CAS:528:DC%2BD1MXnvF2qtrk%3D 10.1016/j.eururo.2008.11.002 19042080
11. G Kemmler B Holzner M Kopp M Dunser R Margreiter R Greil B Sperner-Unterweger 1999 Comparison of two quality-of-life instruments for cancer patients: the Functional Assessment Of Cancer Therapy-General and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 J Clin Oncol 17 2932 2940 1:STN:280:DC%2BD3c%2FjtVWjsA%3D%3D 10561373
12. D Osoba G Rodrigues J Myles B Zee J Pater 1998 Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 139 144 1:STN:280:DyaK1c7gtFKrtw%3D%3D 9440735
13. PW Sullivan PM Mulani M Fishman D Sleep 2007 Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer Qual Life Res 16 571 575 10.1007/s11136-006-9156-2 17294287 (Pubitemid 46474953)
14. S Yount D Cella D Banik T Ashraf D Shevrin 2003 Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI) Health Qual Life Outcomes 1 69 10.1186/1477-7525-1-69 14633279 (Pubitemid 39111927)